These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25810360)

  • 1. 4D MRI of polycystic kidneys from rapamycin-treated Glis3-deficient mice.
    Xie L; Qi Y; Subashi E; Liao G; Miller-DeGraff L; Jetten AM; Johnson GA
    NMR Biomed; 2015 May; 28(5):546-54. PubMed ID: 25810360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD).
    Zafar I; Belibi FA; He Z; Edelstein CL
    Nephrol Dial Transplant; 2009 Aug; 24(8):2349-53. PubMed ID: 19321761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of MR images of mice in preclinical treatment monitoring of polycystic kidney disease.
    Hadjidemetriou S; Reichardt W; Buechert M; Hennig J; von Elverfeldt D
    Med Image Comput Comput Assist Interv; 2009; 12(Pt 2):665-72. PubMed ID: 20426169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four-dimensional MRI of renal function in the developing mouse.
    Xie L; Subashi E; Qi Y; Knepper MA; Johnson GA
    NMR Biomed; 2014 Sep; 27(9):1094-102. PubMed ID: 25066408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glis3 is associated with primary cilia and Wwtr1/TAZ and implicated in polycystic kidney disease.
    Kang HS; Beak JY; Kim YS; Herbert R; Jetten AM
    Mol Cell Biol; 2009 May; 29(10):2556-69. PubMed ID: 19273592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphologic and dynamic renal imaging with assessment of glomerular filtration rate in a pcy-mouse model using a clinical 3.0 Tesla scanner.
    Sadick M; Schock D; Kraenzlin B; Gretz N; Schoenberg SO; Michaely HJ
    Invest Radiol; 2009 Aug; 44(8):469-75. PubMed ID: 19465861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats.
    Sabbatini M; Russo L; Cappellaio F; Troncone G; Bellevicine C; De Falco V; Buonocore P; Riccio E; Bisesti V; Federico S; Pisani A
    Am J Physiol Renal Physiol; 2014 May; 306(10):F1243-50. PubMed ID: 24647711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.
    Zafar I; Ravichandran K; Belibi FA; Doctor RB; Edelstein CL
    Kidney Int; 2010 Oct; 78(8):754-61. PubMed ID: 20686448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease.
    Novalic Z; van der Wal AM; Leonhard WN; Koehl G; Breuning MH; Geissler EK; de Heer E; Peters DJ
    J Am Soc Nephrol; 2012 May; 23(5):842-53. PubMed ID: 22343118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease.
    Ta MH; Schwensen KG; Foster S; Korgaonkar M; Ozimek-Kulik JE; Phillips JK; Peduto A; Rangan GK
    PLoS One; 2016; 11(10):e0164193. PubMed ID: 27723777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring kidney and renal cyst volumes applying MR approaches on a rapamycin treated mouse model of ADPKD.
    Reichardt W; Romaker D; Becker A; Buechert M; Walz G; von Elverfeldt D
    MAGMA; 2009 Jun; 22(3):143-9. PubMed ID: 19107537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal expression of a transforming growth factor-alpha transgene accelerates the progression of inherited, slowly progressive polycystic kidney disease in the mouse.
    Gattone VH; Kuenstler KA; Lindemann GW; Lu X; Cowley BD; Rankin CA; Calvet JP
    J Lab Clin Med; 1996 Feb; 127(2):214-22. PubMed ID: 8636651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
    Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
    Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic resonance T2 mapping and diffusion-weighted imaging for early detection of cystogenesis and response to therapy in a mouse model of polycystic kidney disease.
    Franke M; Baeßler B; Vechtel J; Dafinger C; Höhne M; Borgal L; Göbel H; Koerber F; Maintz D; Benzing T; Schermer B; Persigehl T
    Kidney Int; 2017 Dec; 92(6):1544-1554. PubMed ID: 28754558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Volumetric analysis of MRI data monitoring the treatment of polycystic kidney disease in a mouse model.
    Hadjidemetriou S; Reichardt W; Hennig J; Buechert M; von Elverfeldt D
    MAGMA; 2011 Apr; 24(2):109-19. PubMed ID: 21213015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus therapy for patients with adult polycystic kidney disease: a pilot study.
    Soliman AR; Ismail E; Zamil S; Lotfy A
    Transplant Proc; 2009 Nov; 41(9):3639-41. PubMed ID: 19917358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of paclitaxel on the progression of polycystic kidney disease in rodents.
    Martinez JR; Cowley BD; Gattone VH; Nagao S; Yamaguchi T; Kaneta S; Takahashi H; Grantham JJ
    Am J Kidney Dis; 1997 Mar; 29(3):435-44. PubMed ID: 9041221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acceleration of polycystic kidney disease progression in cpk mice carrying a deletion in the homeodomain protein Cux1.
    Alcalay NI; Sharma M; Vassmer D; Chapman B; Paul B; Zhou J; Brantley JG; Wallace DP; Maser RL; Vanden Heuvel GB
    Am J Physiol Renal Physiol; 2008 Dec; 295(6):F1725-34. PubMed ID: 18829740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tracking kidney volume in mice with polycystic kidney disease by magnetic resonance imaging.
    Wallace DP; Hou YP; Huang ZL; Nivens E; Savinkova L; Yamaguchi T; Bilgen M
    Kidney Int; 2008 Mar; 73(6):778-81. PubMed ID: 18185504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury.
    Aihara M; Fujiki H; Mizuguchi H; Hattori K; Ohmoto K; Ishikawa M; Nagano K; Yamamura Y
    J Pharmacol Exp Ther; 2014 May; 349(2):258-67. PubMed ID: 24570071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.